Esketamine with preparation and integration therapy for treatment-resistant depression
Esketamine With or Without Psychedelic Preparation and Integration for Treatment-Resistant Depression: A Randomized Controlled Trial
This study will test whether adding brief preparation and follow-up integration therapy to FDA-approved esketamine nasal spray helps adults with treatment-resistant depression feel better and keep improving longer.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 21 Years to 65 Years |
| Sex | All |
| Sponsor | University of Puerto Rico Academic / other |
| Locations | 2 sites (San Juan and 1 other locations) |
| Trial ID | NCT07369102 on ClinicalTrials.gov |
What this trial studies
This is a single-site, randomized, controlled trial in San Juan, Puerto Rico comparing two approaches for adults with treatment-resistant depression who receive FDA‑approved intranasal esketamine twice weekly. All participants receive standard clinical dosing and monitoring; half are randomly assigned to brief, manualized preparation and integration sessions delivered by a trained clinician while the other half receive standard care without those extra sessions. The integration sessions are informed by psychedelic-assisted therapy frameworks and aim to improve safety, emotional processing, and meaning‑making around the esketamine experience. The primary outcome is change in depression severity on the MADRS, with secondary measures including emotional regulation, therapeutic alliance, treatment acceptability, and dissociative experiences.
Who should consider this trial
Good fit: Adults aged 21–65 with DSM‑5 major depressive disorder who meet treatment‑resistant criteria (failure of at least two adequate antidepressant trials), have baseline MADRS ≥30, and are clinically stable for outpatient esketamine care.
Not a fit: People requiring inpatient-level care for active suicidality, those with unstable medical or psychiatric conditions, individuals outside the 21–65 age range, pregnant people, or those unwilling/unable to attend twice-weekly in-person visits are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, adding brief preparation and integration sessions could increase symptom reduction, prolong the benefits of esketamine, and improve patient understanding and treatment acceptability.
How similar studies have performed: Esketamine nasal spray is FDA-approved and effective for many with TRD, while randomized evidence that brief integration therapy adds durable benefit is limited though smaller ketamine and psychedelic-assisted therapy studies have shown promising signals.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: Adults aged 21 to 65 years. * Diagnosis: Current Major Depressive Disorder (MDD) as confirmed by Structured Clinical Interview for DSM5 (SCID-5). * Treatment Resistance: Failure to achieve remission with at least two antidepressants of adequate dose and duration (TRD criteria) as confirmed by SCID-5. * Symptom Severity: Baseline Montgomery-Åsberg Depression Rating Scale (MADRS) ≥30. * Suicidal Ideation: Participants with baseline passive or active suicidal ideation may be included, provided they do not meet criteria for inpatient admission and are deemed clinically stable for outpatient care. This will be measured with the Columbia Suicide Severity Rating Scale (C-SSRS). * Consent: Ability to understand and voluntarily provide written informed consent. * Contraception: For participants of reproductive potential, willingness to use at least one highly effective method of contraception (e.g., intrauterine device, hormonal contraception, sterilization) or two effective methods (e.g., barrier method plus spermicide) during the study and for at least one month after the final esketamine dose. Contraceptive method(s) will be documented at baseline via self-report on a standardized form and reaffirmed at each esketamine session by research staff. Participants who become pregnant or are unable to confirm adequate contraception will be withdrawn from the study for safety reasons. * Availability: Willingness and ability to attend all scheduled sessions and complete study procedures. * Motivation for Engagement: Demonstrates willingness and psychological readiness to engage in guided reflective work before and after esketamine dosing (as assessed during clinical intake). Exclusion Criteria: * Acute Suicide Risk: Immediate need for inpatient psychiatric hospitalization due to suicidal ideation with plan or intent as identified through the C-SSRS. * Psychotic or Bipolar Disorders: Current diagnosis of bipolar I disorder (manic phase), schizophrenia, schizoaffective disorder, or other primary psychotic disorders if stated by participants as a past diagnosis or identified during the SCID-5. * Substance Use Disorder: Active moderate to severe substance use disorder (except nicotine) in the past 6 months as self-identified by participant or during the SCID-5. * Cognitive/Developmental Impairments: Intellectual disability, dementia, or other cognitive/developmental disorders that impair ability to engage meaningfully in structured psychotherapeutic sessions such as preparation or integration, per clinician judgment. * Medical Contraindications: Any medical condition judged to pose undue risk during esketamine administration (e.g., aneurysmal vascular disease, arteriovenous malformation, history of intracerebral hemorrhage, or hypersensitivity to esketamine/ketamine). * Pregnancy/Breastfeeding: Current pregnancy or breastfeeding. * Ongoing Structured Psychotherapy Likely to Confound Outcomes: Participation in any formal psychotherapy within the past 3 months that involves structured, weekly sessions focused on behavioral change or emotional processing (e.g., CBT, ACT, psychodynamic therapy), unless the therapy was completed or stabilized at a low-intensity level for at least 8 weeks prior to enrollment. * Prior Non-Response to Esketamine: Six or more prior esketamine (≥56 mg) or IV ketamine sessions (0.4-0.7 mg/kg) without clinical response. * Recent Ketamine Use: Use of ketamine/esketamine in the past 12 weeks. * Inability to Consent: Any condition rendering the participant unable to provide informed consent. * Prior Enrollment: Previous participation in this study.
Where this trial is running
San Juan and 1 other locations
- Pravan Foundation — San Juan, Puerto Rico (Recruiting)
- University of Puerto Rico, Department of Psychiatry — San Juan, Puerto Rico (Recruiting)
Study contacts
- Study coordinator: Paulina D Rullan-Farinacci, MD
- Email: paulina.rullan@upr.edu
- Phone: 787-414-3571
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.